Flexofytol, a Purified Curcumin Extract, in Fibromyalgia and Gout: A Retrospective Study*

Thierry Appelboom¹, Christian Mélot MsciBiost²

¹Rheumatology Department, Erasme University Hospital, Medical School, University of Brussels, Brussels, Belgium; ²Emergency Department, Erasme University Hospital, Medical School, University of Brussels, Brussels, Belgium.

Received February 26th, 2013; revised March 28th, 2013; accepted April 9th, 2013

Copyright © 2013 Thierry Appelboom, Christian Mélot MscBiost. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Flexofytol is a recently-purified curcumin extract administered as a food supplement with the indication for being “able to improve musculoskeletal flexibility and preserve articular function”. It is now marketed in Belgium, frequently used with success in daily clinical practice according to pharmacists, and also prescribed by general practitioners and rheumatologists for various painful conditions. The objective of this retrospective study was to evaluate the potential efficacy of the compound in fibromyalgia and gout from our practice from 2011-2012. Accordingly, the medical files of 116 patients (83 with a follow-up of 1 to 12 months) with fibromyalgia or gout who were treated with Flexofytol were analysed to determine whether they had benefited from this therapy or had experienced undesirable effects. Flexofytol provided a benefit in acute gout crisis and fibromyalgia. Interestingly, the clinical improvement was rapid (within 24-48 h), with good efficacy in gout. The benefit of Flexofytol was on different manifestations of pain rather than on the sleep disorders of fibromyalgia. Except for some occasional difficulties with tablet swallowing and transient diarrhoea, the treatment was well tolerated. In conclusion, Flexofytol appears to be an alternative to conventional treatment for fibromyalgia and gout.

Keywords: Curcumin; Fibromyalgia; Gout

1. Introduction

Flexofytol is a recently purified curcumin extract licensed and marketed by Tilman Laboratory (Belgium). Essentially, it contains diferuloylmethane and 2 derived compounds, demethoxycurcumin and bismethoxycurcumin. In order to facilitate intestinal absorption, the tablet (42 mg) is supplemented with polysorbate as an emulsifier, and citric acid as a pH stabilizer. Consequently, the solubility of Flexofytol is 7500 times greater than that of Curcuma.

The toxicity of Curcuma remains unknown, but dosages of 12 g daily have been administered for more than 3 months without side effects. A systematic review of curcumin toxicity performed in 2003 concluded that there was an absence of toxicity for dosages up to 8 g daily, and that the compound has an anti-inflammatory effect. On the other hand, Curcuma claims to exert protective effects on the gastric mucosa, and to probably have a cicatrizing effect on gastric ulcers (European Commission for Health). In traditional therapy, Curcuma is used in the treatment of rheumatic pain and other clinical conditions including Cancer, Helicobacter pylori infection, scabies [1-4].

The ancient curry spice known as turmeric and its bioactive component, curcumin have been revered in the world of Ayurvedic medicine for more than 2500 years. Curcuma is thought to prevent digestive cancers, improve measures of cognition and brain health, including Parkinson’s and Alzheimer’s, and to be a maintenance therapy in ulcerative colitis [5,6].

The high number of Flexofytol tablets sold in Belgium reflects a high degree of satisfaction among patients. Now, Flexofytol is also prescribed by physicians in daily practice, and improvement in diffuse pain, lower back pain, tendonitis, and arthritis associated with
Flexofytol is frequently reported. For these reasons, we performed a retrospective analysis of our own experiences, and assessed the tolerance of the compound from our medical files of patients with fibromyalgia and gout.

2. Patients and Methods

Our population consisted of 116 patients treated during the end of 2011 and the beginning of 2012 with Flexofytol 4 tablets daily for fibromyalgia (n = 62) and gout (n = 54), with a follow up visit after a period of 4 - 6 weeks for 83 (42%) patients. The following information was recorded from the medical files: age, sex, and global assessment of possible benefit. In fibromyalgia, additional information generally available included the following questions: can you rate between 0 (no) and 10 (full) the severity of your symptoms (diffuse pain, fatigue, morning fatigue, abnormal fatigability, headache, dizziness, thoracic oppression, muscle cramps, paraesthesia in the limbs, intolerance to contact, noise, and odours), and the tender points count. The presence of side effects was also recorded.

Statistical Analysis

The data were presented as a histogram and as medians with interquartile ranges (IQR) before and after treatment. The medians were compared using a nonparametric test for repeated measures (Wilcoxon signed rank test). The percentage of responses before and after treatment was compared using z-test. A p-value < 0.05 was considered significant.

3. Results

3.1. Effect of Flexofytol in Fibromyalgia

Among the 62 patients treated with Flexofytol 4 tablets daily, 41 felt that the therapy was beneficial. In the clinical setting of fibromyalgia, diffuse pain and fatigue are central. Therefore, it seemed interesting to look for an effect on these symptoms in particular. Indeed, Flexofytol reduced diffuse pain intensity, with the median (IQR) shifting from 8 (7 - 8) to 6 (5 - 8) (p = 0.003) (Figure 1). A benefit was also observed on fatigue; the median (IQR) indicates a reduction from 8 (6 - 8) to 7 (5 - 8) (p = 0.0392) (Figure 2). Concerning morning fatigue, which is often reported by these patients, the difference was not significant (p = 0.0625) despite a reduction in the median from 8 (7 - 8) to 6.5 (3.75 - 9). On the other hand, fatigue during domestic work improved with a reduction in median (IQR) from 8 (5 - 9) to 7.5 (5.25 - 8) (p = 0.0143).

Among the other symptoms of fibromyalgia, an important reduction in dizziness was noted, with a median (IQR) reduction from 5 (2 - 8) to 3 (1 - 7) (p = 0.0258), as well as in thoracic oppression with a median decrease from 7 (6 - 8) to 5 (2.5 - 7) (p = 0.0015), heart palpitations with a median reduction from 6 (3.75 - 8) to 5 (2 - 6) (p = 0.004), cramps from 6 (4 - 8) to 4.5 (2 - 7) (p = 0.0096), and paraesthesia in the extremities from 7 (4 - 8) to 4 (1 - 7) (p = 0.0018).

On the other hand, no significant benefit was observed for headache, which remained unchanged from 6.5 (3 - 8) to 6.5 (2 - 8)(p = 0.1477), perception of painful skin contact from 8 (6 - 8) to 7 (5 - 8) (p = 0.3343), intolerance to noise from 7 (4.75 - 8.25) to 7.5 (5-8) (p = 0.4412), or to odours from 6 (0 - 8) to 5 (0 - 7) (p = 0.025). Tender points, which are cardinal for the diagnosis of fibromyalgia and represent diagnostic criteria, were not modified by treatment, with medians (IQR) ranging from 18 (18 - 18) to 18 (8 - 18) (p = 0.1814).

3.2. Effect of Flexofytol in Gout

With Flexofytol, 17/19 gout patients reported dramatic...
improvements in acute gout symptoms within 24 - 48 h with 4-6 Flexofytol tablets daily (p = 0.0002) (Figure 3). Eleven patients decided to spontaneously continue therapy to prevent recurrence by taking 2 tablets daily for 3 - 6 months, and 10/11 were satisfied after 6 months.

3.3. Undesirable Effects

Some patients reported difficulties swallowing the tablets (n = 4/83), slight diarrhoea (n = 5/83), and skin itchiness (n = 1/83) that spontaneously resolved when the dosage was reduced from 4 to 2 tablets daily. When blood testing could be obtained (51/83), no alteration in renal, liver, or hematopoietic function was noted.

3.4. Drug Interaction

Our experience is limited, but so far no drug interaction was reported with warfarin (n = 2) or antidiabetic agents (n = 4).

4. Discussion

The most benefit seen with Flexofytol was observed in gout, with a majority of patients (17/19) reporting that they experienced clinical improvement within 24 - 48 h, which was similar to that obtained with non-steroidal anti-inflammatory drugs (NSAIDs). It is important to note that some patients decided to take 6 tablets daily rather than 4 because they considered that a benefit was present, but insufficient with the regular dose. Since this first experience, 20/23 additional patients (not included in this study) reported a benefit from Flexofytol, and confirmed excellent pain relief within 1 or 2 days. The same group decided spontaneously to adopt Flexofytol as maintenance therapy because they felt that it provided a protective effect against the recurrence of gout crisis (data not shown).

In patients with fibromyalgia, a high proportion of patients reported experiencing clinical improvement. Interestingly, some symptoms were more improved than others.

Figure 3. Gout: number of patients improved (p = 0.0002).
Flexofytol could represent a safe and efficacious alternative to drawing any definitive conclusion. Yet, if confirmed, dissatisfied with the treatment is unknown. If a placebo was lost to follow up, and whether they were satisfied or dissatisfied with the treatment is unknown. If a placebo effect is likely, it is balanced by the high number of fibromyalgia patients who are depressed, rarely express satisfaction with therapy, or do not comply with the treatment plan.

The mode of action of Flexofytol in fibromyalgia is difficult to explain. Interestingly, improvement was noted in decreasing order for paraesthesia, diffuse pain, dizziness, cramps, thoracic oppression, palpitations, and less significantly for fatigue during effort. No effect on headache, intolerance to contact, noise, or on the number of tender points was recorded.

Under these conditions, Flexofytol would play a role in reducing pain rather than affecting sleep. As a hypothesis, the target of Flexofytol could be the grey nuclei of the brain, which play a more central role in pain control than the limbic system, which is active in sleep control.

In conclusion, in this retrospective, real-life study in patients with gout and fibromyalgia, Flexofytol provided a benefit without adverse effects. These results need to be confirmed, and double-blind trials are necessary prior to drawing any definitive conclusion. Yet, if confirmed, Flexofytol could represent a safe and efficacious alternative treatment in these conditions.

REFERENCES


Copyright © 2013 SciRes.